372117-76-5

Basic information

• Product Name: ethyl 4-(3-chloro-4-MethoxybenzylaMino)-2- (Methylsulfonyl) pyriMidine-5-carboxylate
• Synonyms: ethyl 4-(3-chloro-4-MethoxybenzylaMino)-2- (Methylsulfonyl) pyriMidine-5-carboxylate;4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylsulfonyl)-5-Pyrimidinecarboxylic acid ethyl ester
• CAS NO: 372117-76-5
• Molecular Formula: C₁₆H₁₈ClN₃O₅S
• Molecular Weight: 399.84922
• Mol File: 372117-76-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 4-(3-chloro-4-MethoxybenzylaMino)-2- (Methylsulfonyl) pyriMidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(3-chloro-4-MethoxybenzylaMino)-2- (Methylsulfonyl) pyriMidine-5-carboxylate(372117-76-5)
• EPA Substance Registry System: ethyl 4-(3-chloro-4-MethoxybenzylaMino)-2- (Methylsulfonyl) pyriMidine-5-carboxylate(372117-76-5)

Safety Data

• Hazardous Substances Data: 372117-76-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-(3-chloro-4-methoxybenzylamino)-2-(methylsulfonyl)pyrimidine-5-carboxylate serves as a crucial building block for the synthesis of a variety of drugs. Its unique functional groups and structural features make it particularly valuable in the development of medications that target specific enzymes or receptors within the body, potentially leading to more effective treatments for various diseases and conditions.

Upstream product

• 115514-77-7 (3-chloro-4-methoxyphenyl)methanamine 
• 53554-29-3 ethyl 4-hydroxy-2-(methylthio)pyrimidine-5-carboxylate 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 330785-81-4 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-2-(methylsulfanyl)pyrimidine-5-carboxylate 

Downstream Products

• 330786-00-0 2-chloro-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine 
• 330784-47-9 avanafil 
• 1638497-22-9 ethyl (S)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)tetrahydropyrrole-1-yl)-5-pyrimidinecarboxylate 
• 1638497-22-9 C₂₀H₂₅ClN₄O₄ 
• 330785-99-4 2-hydroxy-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine 
• 372117-77-6 2-(2-pyridylmethoxy)-5-(2-pyridylmethoxycarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine 
• 372113-45-6 2-(2-pyridylmethoxy)-5-ethoxycarbonyl-4-(3-chloro-4-methoxybenzylamino)pyrimidine 
• 330785-84-7 4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]pyrimidine-5-carboxylic acid 

Relevant articles and documents

Preparation method of pharmaceutical compound avanafil

The invention discloses a preparation method of a pharmaceutical compound avanafil, and belongs to the technical field of synthesis of pharmaceutical compounds. The key point of the technical scheme of the invention is as follows: a synthesis route of the synthetic method of the pharmaceutical compound avanafil is shown in the specification. The synthetic method has the advantages that the yield is high, the cost is low, the method is economical and environmentally friendly and is suitable for industrialization, the product purity is high and the like, and the method is a synthetic method withindustrial production values.

Method of preparing medical compound stendra

The invention discloses a method of preparing a medical compound stendra and belongs to the technical field of medical compounds. The key point of the technical scheme is as follows: the synthetic route of the method of preparing the medical compound stendra is as follows: a formula as shown in the description. The method has the advantages of being high in yield, low in cost, economical and environment-friendly, suitable for industrialization, high in product impurity and the like, and is a synthetic method which has industrial production value.

The discovery of avanafil for the treatment of erectile dysfunction: A novel pyrimidine-5-carboxamide derivative as a potent and highly selective phosphodiesterase 5 inhibitor

Novel pyrimidine-5-carboxamide derivatives bearing a 3-chloro-4-methoxybenzylamino group at the 4-position were identified as potent and highly selective phosphodiesterase 5 inhibitors. Among them, we successfully found 10j (avanafil) which exhibited a potent relaxant effect on isolated rabbit cavernosum (EC30 = 2.1 nM) and a high isozyme selectivity.

Cyclic compounds

1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.